QLT has positive outcomes treating LCA

QLT (NASDAQ:QLTI; TSX:QLT) has released “positive outcomes” from interim results of the first three subjects enrolled in a Phase 1b clinical proof-of-concept study of its QLT091001 treatment for Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease. LCA leads to retinal dysfunction and significant visual impairment beginning at birth.  Based on the positive results [...]

Cormark ups Transition price target 52%

Cormark Securities raised its target price on “buy-rated” Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to $8 from $5.25, saying it believes Irish partner Elan is likely to move Transition’s ELND005 drug forward into a Phase 3 clinical trial in Alzheimer’s disease.  The stock closed at $3.50 on the TSX Friday. An imbalance of deaths in an ongoing [...]

Cannasat changes name to Cynapsus Therapeutics

Cannasat Therapeutics (TSX-V:CTH) received shareholder approval to change its corporate name to Cynapsus Therapeutics, with no change to the stock symbol. In a statement, CEO Anthony Giovinazzo said the new name, which is drawn loosely from the word “synapse,” more accurately reflects the company’s new focus and direction on treatments for central nervous system diseases [...]

In conversation with Dr. Erich Mohr

Dr. Erich Mohr enjoyed his time in academia as a neuropsychologist at the U.S. National Institutes of Health and University of Ottawa.  But he couldn’t resist the entrepreneurial call when it came knocking in 1996. Teaming up with a good friend, they formed CroMedia Global, a contract research organization that grew to 550 employees in [...]

DiagnoCure names president for U.S. lab unit

DiagnoCure Inc. (TSX:CUR) has appointed Valerie Palmieri as president of DiagnoCure Oncology Laboratories, its U.S. subsidiary. Ms. Palmieri brings more than 25 years experience in the laboratory industry to DiagnoCure, including several executive positions at DIANON Systems and Laboratory Corp. of America.  For the past year, Ms. Palmieri was a consultant with Momentum Consulting, which [...]

Cannasat plans $2.5 million private placement

Cannasat Therapeutics (TSX-V:CTH) plans to raise $2.5 million through a brokered private placement of units priced at 10 cents each, with Wellington West Capital as lead placement agent. Each unit will consist of one common share and one-half of a warrant of Cannasat.  One warrant entitles the holder to purchase an additional common share at [...]

Angiotech buys Haemacure assets

Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) has closed the acquisition of certain product candidates and technology assets of insolvent Haemacure, which will allow it to pursue the commercialization of Haemacure’s human biomaterial product candidates – fibrin sealant and thrombin hemostat. Last June, Angiotech provided Haemacure with a $2.5 million (U.S.) senior secured bridge loan as part of [...]

Ondine raises $750,000 in private placement

Ondine Biopharma (TSX:OBP) has issued 12,530,000 units at a price of six cents each for gross proceeds of $750,000 in a tranche under a non-brokered private placement of up to 13,800,000 units, which would raise a total of $830,000. Each unit consists of one common share and one warrant, entitling the holder to acquire an [...]

BioFinance 2010, Toronto, April 6-8: biotuesdays.com Will Be There

BioFinance is a leading investor conference in Canada for the life sciences industry.  This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector.  Presenting companies will span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, [...]

TearLab readies overhaul of dry eye market

In the 1990s, Elias Vamvakas turned TLC Laser Vision into a medical success story, freeing hundreds of thousands of people from wearing glasses and contact lenses.  Now, he’s back at the helm of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB)) with a groundbreaking diagnostic test for dry eye disease or DED. “While laser vision correction surgery was [...]

« Previous Page — Next Page »